

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Precision Oncology: Translating Discovery to the Clinic (EK45)

June 21-24, 2021 • Virtual at your computer

Scientific Organizers: Klaus Hoeflich, Scott Lowe and Alice Shaw

Sponsored by BioLegend, Inc., Genentech, Inc., Infinity Pharmaceuticals, Inc. and Thermo Fisher Scientific Inc.

MONDAY, JUNE 21

Welcoming Remarks and Keynote Address (7am Denver/Mountain Time Start)

***Klaus P. Hoeflich**, Nested Bio, USA

Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, USA
Lineage Plasticity: Lessons from Prostate Cancer

Clinical Genomics (7:40am Denver/Mountain Time Start)

***Scott W. Lowe**, Memorial Sloan Kettering Cancer Center, USA

***Todd R. Golub**, Broad Institute, USA
Pre-Clinical Approaches to Cancer Precision Medicine

Elli Papaemmanuil, Memorial Sloan Kettering Cancer Center, USA
Leukemia Genomics

Jaclyn A. Biegel, Children's Hospital Los Angeles and Keck School of Medicine of USC, USA
Personalized Genomic Testing in Pediatric Oncology

Targeting Novel Mechanisms (9:15am Denver/Mountain Time Start)

***Todd R. Golub**, Broad Institute, USA

John V. Heymach, University of Texas MD Anderson Cancer Center, USA
LKB1/STK11 Axis in Precision Immunotherapy

Arvin C. Dar, Icahn School of Medicine at Mount Sinai, USA
Structural Basis for the Action of Clinical MEK Inhibitors at KSR-Bound MEK

***Scott W. Lowe**, Memorial Sloan Kettering Cancer Center, USA
Non-Cell Autonomous Tumor Control via Senescence

Brian Schwartz, Infinity Pharmaceuticals, Inc., USA
Short Talk: Eganelisib (IPI-549) Activity as a Macrophage Reprogramming Therapeutic Candidate in 1L Metastatic TNBC, 2L Metastatic Urothelial Cancer and Other Solid Tumors

Triparna Sen, Memorial Sloan Kettering Cancer Center, USA
Short Talk: SCD1-Regulated Ferroptosis as a Novel Therapeutic Strategy in Non-Small Cell Lung Cancer

Poster Session (12pm Denver/Mountain Time Start)

TUESDAY, JUNE 22

Emerging Technologies I (7am Denver/Mountain Time Start)

***Alice T. Shaw**, Novartis Institutes for Biomedical Research, Inc., USA

Valsamo Anagnostou, Johns Hopkins University School of Medicine, USA
Harnessing Tumor Evolution and Immune Responses to Treat Lung Cancer

Gromoslaw A. Smolen, Celsius Therapeutics, USA
Single Cell Genomics Technologies in the Clinic – Challenges and Opportunities

***Nicola Aceto**, ETH Zürich, Switzerland
Biology and Vulnerabilities of Circulating Tumor Cells

Cigall Kadoch, Dana-Farber Cancer Institute, Harvard Medical School, USA

Structure and Function of Mammalian SWI/SNF Chromatin Remodeling Complexes in Human Cancer

Ramya Sridharan, Weill Cornell Medical, USA
Short Talk: Nano-Targeted Kinase Inhibitor Treatment of KRAS Mutant Lung Cancer

Xin Jin, Broad Institute of MIT and Harvard, USA
Short Talk: A Metastasis Map of Human Cancer Cell Lines

Clinical Trials and Overcoming Resistance (9:20am Denver/Mountain Time Start)

***Nicola Aceto**, ETH Zürich, Switzerland

***Alice T. Shaw**, Novartis Institutes for Biomedical Research, Inc., USA
Resistance to Non-Small Cell Lung Cancer Therapies

Lori Friedman, ORIC Pharmaceuticals, USA
Targeted EGFR/HER2 Therapy to Overcome the Blood-Brain Barrier

Jessica J. Lin, Massachusetts General Hospital, USA
Defining Mechanisms of Resistance to KRASG12C Inhibitors

Nikhil Wagle, Dana-Farber Cancer Institute, USA
Mechanisms of Resistance to Endocrine Therapy and CDK4/6 Inhibitors in ER+ Breast Cancer

Meet the Editors (12pm Denver/Mountain Time Start)

Sara Hamilton, Cell Press, USA

Avital Lev, NIAID, National Institutes of Health, USA

Lise Roth, European Molecular Biology Organization, Germany

Miguel Foronda, Nature Cancer, USA

WEDNESDAY, JUNE 23

Emerging Technologies II (7am Denver/Mountain Time Start)

***Jason S. Carroll**, Cancer Research UK, University of Cambridge, UK

Priti Hegde, Foundation Medicine, USA
Driving Precision Medicine through Clinical Computational Oncology

***Russell W. Jenkins**, Massachusetts General Hospital, USA
Organotypic Modeling of Cancer and Immune Cell Dynamics

Nir Yosef, University of California, Berkeley, USA
Inferring and Making Sense Out of Cancer Cell Phylogenies

Nathanael Gray, Stanford University, USA
Targeted Protein Degradation- A New Approach for Challenging Targets

Hannah Julia Uckelmann, Dana-Farber Cancer Institute, USA
Short Talk: MLL-Menin Inhibition Reverses Pre-leukemic Progenitor Self-renewal in NPM1 Mutant AML

Targeting Gene Transcription (9:10am Denver/Mountain Time Start)

***Russell W. Jenkins**, Massachusetts General Hospital, USA

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Precision Oncology: Translating Discovery to the Clinic (EK45)

June 21-24, 2021 • Virtual at your computer

Scientific Organizers: Klaus Hoeflich, Scott Lowe and Alice Shaw

Sponsored by BioLegend, Inc., Genentech, Inc., Infinity Pharmaceuticals, Inc. and Thermo Fisher Scientific Inc.

Christopher Vakoc, Cold Spring Harbor Laboratory, USA
Transcription Factor Addiction

***Jason S. Carroll**, Cancer Research UK, University of Cambridge, UK
Proteomic Analysis of Chromatin Remodeling Complexes

Trudy G. Oliver, Huntsman Cancer Institute, USA
Using GEMMs to Identify Therapeutic Vulnerabilities in MYC-Driven Small Cell Lung Cancer

Scott A. Armstrong, Dana-Farber Cancer Institute, USA
Targeting the MLL Complex to Control Gene Expression

Timothy Heffernan, MD Anderson Cancer Center, USA
PRMT1: A Novel Dependency at the Nexus of RNA Metabolism and Cancer

Networking Lounge (11:15am Denver/Mountain Time Start)

THURSDAY, JUNE 24

Novel Therapeutics (7am Denver/Mountain Time Start)

***Scott W. Lowe**, Memorial Sloan Kettering Cancer Center, USA

Martin McMahon, University of Utah School of Medicine, USA
Mechanisms of Resistance to Combined Inhibition of RAS Signaling plus Autophagy in Pancreatic Cancer

***Klaus P. Hoeflich**, Nested Bio, USA
Targeting Protein Kinases in Cancer

Neal Rosen, Memorial Sloan-Kettering Cancer Center, USA
A General Allele-Specific Model for Understanding and Treating Tumors Driven by ERK-Activation

Alberto Bardelli, University of Torino, Italy
High Dose Vitamin C and Inactivation of DNA Repair Boost Cancer Immunotherapy

Radha Mukherjee, Memorial Sloan Kettering, USA
Short Talk: Regulation of PTEN Translation by PI3K Signaling Maintains Pathway Homeostasis

Jordan Young, Repare Therapeutics, Canada
Short Talk: Oncogenic CCNE1 Amplification Is Synthetic Lethal with PKMYT1 Kinase Inhibition

The Future of Precision Oncology (9:35am Denver/Mountain Time Start)

***Klaus P. Hoeflich**, Nested Bio, USA

***Scott W. Lowe**, Memorial Sloan Kettering Cancer Center, USA

Elaine R. Mardis, Nationwide Children's Hospital, USA
Informing Patient Treatment with Clinicogenomic Data

Naoko Takebe, NCI, National Institutes of Health, USA
NCI's Precision Medicines Initiatives

Career Roundtable (12:30pm Denver/Mountain Time Start)

Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center, USA

Christopher Vakoc, Cold Spring Harbor Laboratory, USA

Tracy T. Tang, Vivace Therapeutics, Inc., USA